Xintao Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xintao Tu has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Kun Yang
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
14 shared publications - Nan Yan
Department of Immunology, University of Texas Southwestern Medical Center
14 shared publications - Cong Xing
Department of Immunology, University of Texas Southwestern Medical Center
12 shared publications - Devon Jeltema
Department of Immunology, University of Texas Southwestern Medical Center
12 shared publications - Kennady Knox
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
11 shared publications - Kun Song
University of Texas Southwestern Medical Center 1 Department of Immunology Dallas, TX
11 shared publications
Latest Publications
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Targeting LRRC15-expressing fibroblasts holds therapeutic potential to ameliorate inflammation and fibrosis in autoimmune diseases
Objectives: Targeting stromal cells such as inflammatory fibroblasts presents a potential avenue to alleviate autoimmune inflammation and fibrosis. This study aimed to characterize LRRC15 expression in rheumatoid arthritis (RA) and systemic sclerosis (SSc) across fibroblast subsets and assess whether targeting LRRC15-expressing fibroblasts can be beneficial for the treatment of fibrosis and fibroblast-mediated inflammation. Methods: We conducted transcriptomic analyses of Lrrc15 in bulk and single-cell RNA-seq datasets from RA and SSc. We used flow cytometry, RNA-seq, immunohistochemistry and spatial transcriptomics to define Lrrc15 expression patterns in diseased tissues. We performed in vitro and in vivo assays to elucidate the function of LRRC15 in inflammatory fibroblasts. Results: When compared with healthy controls, we observed a higher activated fibroblast gene signature in RA synovium and SSc skin biopsies that correlated with Lrrc15 expression. Multi-IF imaging highlighted the clustering of LRRC15-expressing fibroblasts within tertiary lymphoid structures (TLS) in RA synovium. Knockdown of Lrrc15 in primary cells reduced production of TNF-α induced inflammatory chemokines including CCL3 and CXCL10. We confirmed LRRC15 upregulation in mouse models of wound healing and pulmonary fibrosis. Inflammatory fibroblasts with high LRRC15 expression were susceptible to NK cell-mediated LRRC15 specific lysis in vitro. Conclusion: Targeting LRRC15+ fibroblasts and fibrotic microenvironment may offer a new therapeutic opportunity to reduce inflammation in RA, SSc and other autoimmune disorders where activated fibroblasts play a role in disease pathogenesis.
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Targeting LRRC15-expressing fibroblasts holds therapeutic potential to ameliorate inflammation and fibrosis in autoimmune diseases
Objectives: Targeting stromal cells such as inflammatory fibroblasts presents a potential avenue to alleviate autoimmune inflammation and fibrosis. This study aimed to characterize LRRC15 expression in rheumatoid arthritis (RA) and systemic sclerosis (SSc) across fibroblast subsets and assess whether targeting LRRC15-expressing fibroblasts can be beneficial for the treatment of fibrosis and fibroblast-mediated inflammation. Methods: We conducted transcriptomic analyses of Lrrc15 in bulk and single-cell RNA-seq datasets from RA and SSc. We used flow cytometry, RNA-seq, immunohistochemistry and spatial transcriptomics to define Lrrc15 expression patterns in diseased tissues. We performed in vitro and in vivo assays to elucidate the function of LRRC15 in inflammatory fibroblasts. Results: When compared with healthy controls, we observed a higher activated fibroblast gene signature in RA synovium and SSc skin biopsies that correlated with Lrrc15 expression. Multi-IF imaging highlighted the clustering of LRRC15-expressing fibroblasts within tertiary lymphoid structures (TLS) in RA synovium. Knockdown of Lrrc15 in primary cells reduced production of TNF-α induced inflammatory chemokines including CCL3 and CXCL10. We confirmed LRRC15 upregulation in mouse models of wound healing and pulmonary fibrosis. Inflammatory fibroblasts with high LRRC15 expression were susceptible to NK cell-mediated LRRC15 specific lysis in vitro. Conclusion: Targeting LRRC15+ fibroblasts and fibrotic microenvironment may offer a new therapeutic opportunity to reduce inflammation in RA, SSc and other autoimmune disorders where activated fibroblasts play a role in disease pathogenesis.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Three-prime repair exonuclease 1 (TREX1) is the major DNase in mammalian cells that degrades cytosolic DNA to prevent activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway. Genotoxic stress, DNA damage, and radiotherapy induce TREX1 expression in cancer cells, allowing them to evade innate immune activation of type I IFN–mediated antitumor response. Therefore, targeting TREX1 could represent a potential approach to stimulate antitumor immunity. In this study, we conducted a high-throughput small-molecule inhibitor screen of TREX1 using a cell-free DNase assay. Compound 296 specifically inhibited TREX1 DNase activity at low micromolar concentrations, induced type I IFN signaling in cancer cells, and inhibited tumor growth in mice in an inteferon alpha/beta receptor (IFNAR)–dependent manner. Treatment with compound 296 also stimulated T-cell infiltration into tumors and synergized with immune checkpoint blockade. Trex1 knockout cancer cells elicited robust systemic antitumor immunity through tumor-intrinsic cGAS–STING activation and functioned as autologous cancer vaccines that protected against tumor challenge and metastasis. An inducible whole-body Trex1 knockout mouse model was established to simulate “on-demand” systemic TREX1 inactivation in adult mice. Sustained TREX1 loss suppressed a broad range of solid and metastatic tumors in adult mice without incurring severe immune toxicity, even when combined with immune checkpoint blockade, demonstrating the feasibility of an immune-safe therapeutic window. Together, these data demonstrate the antitumor efficacy and immune safety of multiple therapeutic modalities targeting TREX1, including targeting small-molecule inhibitors of TREX1 and employing TREX1 knockout tumor cells as an autologous cancer vaccine. These approaches should pave the way for developing TREX1-targeted cancer immunotherapies.Significance:Therapeutic modalities targeting TREX1 can activate cGAS-STING signaling and can be incorporated into autologous cancer vaccine designs to improve cancer treatment, supporting the potential of inactivating TREX1 to harness innate immunity.See related commentary by Hanks, p. 2778
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Three-prime repair exonuclease 1 (TREX1) is the major DNase in mammalian cells that degrades cytosolic DNA to prevent activation of the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway. Genotoxic stress, DNA damage, and radiotherapy induce TREX1 expression in cancer cells, allowing them to evade innate immune activation of type I IFN–mediated antitumor response. Therefore, targeting TREX1 could represent a potential approach to stimulate antitumor immunity. In this study, we conducted a high-throughput small-molecule inhibitor screen of TREX1 using a cell-free DNase assay. Compound 296 specifically inhibited TREX1 DNase activity at low micromolar concentrations, induced type I IFN signaling in cancer cells, and inhibited tumor growth in mice in an inteferon alpha/beta receptor (IFNAR)–dependent manner. Treatment with compound 296 also stimulated T-cell infiltration into tumors and synergized with immune checkpoint blockade. Trex1 knockout cancer cells elicited robust systemic antitumor immunity through tumor-intrinsic cGAS–STING activation and functioned as autologous cancer vaccines that protected against tumor challenge and metastasis. An inducible whole-body Trex1 knockout mouse model was established to simulate “on-demand” systemic TREX1 inactivation in adult mice. Sustained TREX1 loss suppressed a broad range of solid and metastatic tumors in adult mice without incurring severe immune toxicity, even when combined with immune checkpoint blockade, demonstrating the feasibility of an immune-safe therapeutic window. Together, these data demonstrate the antitumor efficacy and immune safety of multiple therapeutic modalities targeting TREX1, including targeting small-molecule inhibitors of TREX1 and employing TREX1 knockout tumor cells as an autologous cancer vaccine. These approaches should pave the way for developing TREX1-targeted cancer immunotherapies.Significance:Therapeutic modalities targeting TREX1 can activate cGAS-STING signaling and can be incorporated into autologous cancer vaccine designs to improve cancer treatment, supporting the potential of inactivating TREX1 to harness innate immunity.See related commentary by Hanks, p. 2778
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
RZ score, qAC50 and toxicity of 41 potent TREX1 inhibitors from the small-molecule inhibitor screen
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
RZ score, qAC50 and toxicity of 41 potent TREX1 inhibitors from the small-molecule inhibitor screen
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
TREX1 inhibitors suppress tumor progression in vivo
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
TREX1 inhibitors suppress tumor progression in vivo
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Validation of Trex1-KO and double KO MC38 cells
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Validation of Trex1-KO and double KO MC38 cells
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of inducible Trex1 KO in combination with anti-PD-1 immunotherapy
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of inducible Trex1 KO in combination with anti-PD-1 immunotherapy
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of compound #296
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
In vivo toxicity analysis of compound #296
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Immune cell infiltration in tumors treated with compound #296
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Immune cell infiltration in tumors treated with compound #296
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Gating strategy used in Figure 6
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
Gating strategy used in Figure 6